The clinicopathological characteristics of C4orf47 gene were analyzed using the Kaplan-Meier plotter
Clinicopathological characteristics | Overall survival (n = 3,218) | Relapse free survival (n = 2,809) | Progression free survival (n = 3,162) | Disease specific survival (n = 3,189) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N | Hazard ratio | P-value | N | Hazard ratio | P-value | N | Hazard ratio | P-value | N | Hazard ratio | P-value | ||||
SEX | |||||||||||||||
Male | 246 | 2.23 (1.44~3.57) | 0.00031 | 210 | 1.27 (0.84~1.9) | 0.29 | 149 | 1.24 (0.85~1.79) | 0.26 | 244 | 1.85 (1.03~3.31) | 0.035 | |||
Female | 118 | 1.14 (0.65~2.02) | 0.64 | 106 | 1.91 (1.06~3.44) | 0.028 | 121 | 1.86 (1.11~3.09) | 0.016 | 118 | 1.63 (0.8~3.31) | 0.17 | |||
STAGE | |||||||||||||||
I | 170 | 1.62 (0.87~3.03) | 0.13 | 153 | 1.21 (0.68~2.16) | 0.52 | 171 | 1.25 (0.73~2.14) | 0.14 | 168 | 1.16 (0.43~3.08) | 0.77 | |||
I+II | 253 | 1.87 (1.15~3.03) | 0.01 | 228 | 1.4 (0.91~2.16) | 0.12 | 256 | 1.49 (1.01~2.2) | 0.045 | 251 | 2.27 (1.13~4.53) | 0.017 | |||
II | 83 | 1.58 (0.69~3.62) | 0.28 | 75 | 1.57 (0.81~3.06) | 0.18 | 85 | 1.42 (0.77~2.61) | 0.26 | 83 | 6.49 (1.74~24.23) | 0.0015 | |||
II+III | 166 | 1.6 (0.97~2.62) | 0.62 | 145 | 1.36 (0.87~2.13) | 0.17 | 170 | 1.29 (0.86~1.94) | 0.22 | 166 | 2.66 (1.42~4.99) | 0.0015 | |||
III | 83 | 1.58 (0.85~2.93) | 0.15 | 70 | 1.13 (0.62~2.07) | 0.68 | 85 | 0.99 (0.58~1.69) | 0.96 | 83 | 1.81 (0.87~3.8) | 0.11 | |||
III+IV | 87 | 1.48 (0.81~2.7) | 0.2 | 70 | 1.13 (0.62~2.07) | 0.68 | 90 | 1.21 (0.71~2.06) | 0.49 | 87 | 1.71 (0.83~3.51) | 0.14 | |||
IV | 4 | - | - | 0 | - | 5 | - | - | 3 | - | - | ||||
GRADE | |||||||||||||||
I | 65 | 1.13 (0.32~4.08) | 0.85 | 55 | 1.49 (0.44~4.66) | 0.49 | 55 | 1.11 (0.41~3.0) | 0.84 | 55 | 0.69 (0.08~5.54) | 0.72 | |||
II | 174 | 1.74 (1.02~2.97) | 0.04 | 149 | 1.51 (0.93~2.47) | 0.097 | 177 | 1.5 (0.96~2.33) | 0.072 | 171 | 2.1 (1.06~4.17) | 0.03 | |||
III | 118 | 1.68 (0.92~3.07) | 0.09 | 107 | 1.21 (0.71~2.07) | 0.49 | 121 | 1.53 (0.92~2.55) | 0.097 | 119 | 2.8 (1.31~5.99) | 0.0057 | |||
IV | 12 | - | - | 11 | - | - | 12 | - | - | 12 | - | - | |||
AJCC_T | |||||||||||||||
I | 180 | 1.7 (0.94~3.08) | 0.077 | 160 | 1.27 (0.37~2.21) | 0.4 | 181 | 1.29 (0.77~2.15) | 0.33 | 178 | 1.35 (0.57~3.21) | 0.49 | |||
II | 90 | 1.73 (0.81~3.72) | 0.15 | 80 | 1.44 (0.77~2.72) | 0.25 | 93 | 1.41 (0.81~2.47) | 0.23 | 91 | 5.88 (1.87~18.47) | 0.00064 | |||
III | 78 | 1.85 (0.98~3.96) | 0.054 | 67 | 1.12 (0.6~2.1) | 0.71 | 80 | 1.17 (0.66~2.1) | 0.58 | 77 | 1.89 (0.88~4.08) | 0.098 | |||
IV | 13 | - | 6 | - | - | 13 | - | - | 13 | - | - | ||||
Vascular invasion | |||||||||||||||
None | 203 | 1.43 (0.84~2.44) | 0.19 | 175 | 1.1 (0.65~1.84) | 0.73 | 205 | 1.23 (0.77~1.97) | 0.38 | 201 | 1.47 (0.7~3.1) | 0.3 | |||
Micro | 90 | 1.42 (0.65~3.08) | 0.38 | 82 | 0.92 (0.47~1.79) | 0.8 | 92 | 1.02 (0.56~1.83) | 0.96 | 90 | 0.73 (0.22~2.39) | 0.6 | |||
Macro | 16 | - | - | 14 | - | - | 16 | 14 | - | - | |||||
RACE | |||||||||||||||
White | 181 | 1.25 (0.78~2.0) | 0.35 | 147 | 1.22 (0.77~1.93) | 0.4 | 184 | 1.37 (0.92~2.04) | 0.12 | 179 | 1.51 (0.85~2.66) | 0.15 | |||
Asian | 154 | 2.31 (1.26~4.21) | 0.0051 | 145 | 1.89 (1.13~3.15) | 0.014 | 157 | 1.44 (0.88~2.33) | 0.14 | 154 | 2.02 (0.91~4.46) | 0.077 | |||
Alcohol consumption | |||||||||||||||
Yes | 115 | 2.05 (1.06~3.95) | 0.029 | 99 | 1.55 (0.86~2.8) | 0.14 | 117 | 1.12 (0.67~1.89) | 0.66 | 117 | 2.27 (1.07~4.81) | 0.029 | |||
None | 202 | 1.67 (1.05~2.65) | 0.029 | 183 | 1.64 (1.05~2.56) | 0.029 | 205 | 1.76 (1.17~2.64) | 0.0056 | 199 | 1.66 (0.89~3.09) | 0.11 | |||
Hepatitis virus | |||||||||||||||
Yes | 150 | 2.66 (1.34~5.27) | 0.0037 | 139 | 1.6 (0.95~2.69) | 0.074 | 153 | 1.77 (1.1~2.86) | 0.018 | 151 | 2.1 (0.88~5) | 0.086 | |||
None | 167 | 1.22 (0.78~1.91) | 0.39 | 133 | 1.32 (0.8~2.17) | 0.28 | 169 | 1.22 (0.79~1.89) | 0.36 | 165 | 1.38 (0.79~2.42) | 0.26 |